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Abstract 
Multidrug-resistance of bacterial pathogens is a major problem and there is a clear need for 
the development of new types of antibiotics. Here we investigated the antimicrobial activity 
of Ruthenium(II) based DNA-intercalating complexes. These complexes were found to have 
no activity in vitro against the Gram-negative bacterium Escherichia coli, but the complexes 
were clearly active against the Gram-positive bacteria Bacillus subtilis and Staphylococcus 
aureus. In vivo activity has also been demonstrated for one of the compounds using a simple 
infection model, the nematode Caenorhabditis elegans. Importantly, this also showed that the 
compound tested was not toxic to the nematodes. 
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1. Introduction 
Multidrug resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or 
extended spectrum beta lactamase (ESBL) producing Escherichia coli are a significant 
problem in modern healthcare (Karageorgopoulos and Falagas, 2009). Resistance against 
antimicrobial agents develops quickly, even against synthetic compounds that bacteria have 
never encountered previously (Tsiodras et al., 2001). There is therefore a real need to 
continuously look for new types of antibacterial compounds.  
Several avenues are being followed to find new compounds that inhibit growth or 
virulence of pathogenic bacteria. One type of compound that has not been studied in great 
detail are metal complexes. Some early studies showed activity of metal chelates against a 
range of Gram-negative and Gram-positive bacteria (Dwyer et al., 1952; Dwyer et al., 1969). 
In infection models using rodents these compounds showed promise in particular in the 
topical treatment of bacterial infections (Dwyer et al., 1969). Other studies have shown that 
platinum-containing complexes have antibacterial activity. These are, however, quite toxic to 
eukaryotic cells, and compounds such as cisplatin are now mainly used in the treatment of 
cancer (Boulikas and Vougiouka, 2003). We recently showed that a major groove binder, a 
dinuclear iron(II) supramolecular helicate, has activity against Gram-positive bacteria 
(Richards et al., 2009). In that case it was also demonstrated that the helicate was able to bind 
to the chromosomal DNA of bacteria, but it was not clear whether it was DNA-binding alone 
that that lead to its bactericidal activity. 
 Ruthenium(II) polypyridyl complexes do not change structure under physiological 
conditions and are stable in strong acids and bases. They are readily synthesised and in many 
cases can be resolved into stable enantiomeric forms. Ru(II) complexes of the form 
[Ru(PL)2(IL)]2+ (where PL, peripheral ligand; IL, intercalating ligand) have been shown to 
interact with DNA, although the mode and extent of the interactions vary, depending on the 
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type of ligands coordinated and the concentrations used for the binding studies. Spectroscopic 
experiments to elucidate the type, strength, location and geometry of binding of mononuclear 
Ru(II) complexes to DNA were the focus of research in the 1980s and 90s (see Barton, 1985; 
Eriksson et al., 1994; Hiort et al., 1993; Rehmann and Barton, 1990, and references therein). 
These studies have shown that phen (1,10-phenanthroline) as the intercalating ligand is 
amongst the weakest moieties capable of any extent of intercalation. When the intercalating 
ligand is dppz (dipyrido[3,2-a:2'3'-c]phenazine), the complex has much higher affinity for 
DNA due to the greatly increased overlap of the extended phenazine rings with the aromatic 
bases of nucleic acids. The ligands dpq (dipyrido[3,2-d:2’,3’f]quinoxaline and dpqC 
(dipyrido[3,2-a:2'3'-c](6,7,8,9-tetrahydro) phenazine) have affinities between that of phen and 
dppz. Properties of these Ru(II) complexes are also determined by the peripheral ligands, 
which can influence, for instance, DNA binding and/or enantioselectivity. In this study we 
have analysed the antimicrobial activity of three Ru(II) complexes (Fig. 1): 
[Ru(phen)2(dpq)]2+, [Ru(bpy)2(dpqC)]2+ (bpy = 2,2'-bipyridine), and [Ru(2,9-
Me2phen)2(dppz)]2+ (2,9-Me2phen = 2,9-dimethyl-1,10-phenanthroline). We have used 
classical antibiotic resistance tests as well as a nematode infection model and found that in 
particular [Ru(2,9-Me2phen)2(dppz)]2+ has good antimicrobial activity, both in vitro and in 
vivo. 
	   5	  
2. Materials and Methods 
2.1 Strains and growth conditions 
The bacterial strains used in this study are Escherichia coli MC4100 (Peters et al., 2003), 
Bacillus subtilis 168 (Kunst et al., 1997), Enterococcus faecalis BS385 (van Merode et al., 
2006), Enterococcus faecium E1162 (Heikens et al., 2007), and Staphylococcus aureus 
MRSA252, MRSA41 and MSSA160 (Feil et al., 2003). Strains were maintained on Luria-
Bertani (LB) broth (Fisher) or Brain Heart Infusion (BHI) broth (Fisher).  
 
2.2 Synthesis of Ru(II) complexes 
[Ru(phen)2(dpq)]Cl2 (Greguric et al., 1997), [Ru(bpy)2(dpqC)](PF6)2 (Collins et al., 1998), 
and [Ru(2,9-Me2phen)2(dppz)]Cl2 (Greguric et al., 2000) were synthesised and characterised 
as previously described. In all cases racemic mixtures were used in this work.  
 
2.3 Disc susceptibility tests 
Mueller-Hinton (MH; Fisher) agar plates were seeded with approximately 105 bacteria. Discs 
(Whatmann 3MM chromatography paper, 6 mm) impregnated with 30 µg compound were 
applied to these plates. As negative controls discs with solvent only (dimethyl sulfoxide) were 
applied, all of which gave no zone of inhibition. Plates were incubated for 18 hours at 37 oC 
and the diameter of the clearing zone around the discs was measured.  
 
2.4 Minimal inhibitory concentration and minimal bactericidal concentration 
The MIC (minimal inhibitory concentration) values were determined with a macrobroth 
dilution method using MH broth as previously described (Andrews, 2001). MBC (minimal 
bactericidal concentration) values were determined by plating 10 µL of each of the broth 
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cultures from the MIC tests and incubating those plates at 37oC for 24 hours; the MBC was 
defined as the lowest concentration at which no growth was observed.  
 
2.5 Time-kill assays 
Cells were grown to mid-exponential growth phase in MH broth and then diluted to give a 
final concentration of approximately 106 cells per mL. Compound was added and samples 
were taken at regular intervals. To remove the compound, cells were immediately collected 
by centrifugation (2 min at 14,000 g) and washed with fresh medium. The viable count was 
determined by plating serial dilutions, and the number of colony forming units (CFU) per mL 
was calculated. 
 
2.6 C. elegans rescue and toxicity assays 
For nematode infection and rescue assays, a strain that is hypersensitive to pathogens was 
used, Caenorhabditis elegans glp-4(bn2) sek-1(km4) (Moy et al., 2006). The strain, which 
was obtained from the Caenorhabditis Genetics Centre (CGC) at the University of Minnesota, 
also has a mutation leading to temperature-sensitive sterility so that it does not produce any 
progeny during the assay – this simplified the scoring of survival rates. For normal growth 
nematodes were maintained at 15 oC on nematode growth medium, using E. coli OP50 as a 
source of food (Brenner, 1974). For infection, C. elegans worms were age-synchronised by 
isolating eggs through treatment with hypochlorite/NaOH and hatching the eggs overnight in 
M9 buffer (3 g/L KH2PO4, 6 g/L Na2HPO4, 5 g/L NaCl, 0.25 g/L MgSO4.7H2O). Next, 
worms were deposited on lawns of E. coli OP50 grown on NGM plates and incubated at 25 
oC. When worms reached the L4-stage they were removed from the plates with M9 buffer and 
washed 3 times. Approximately 30 worms were deposited in each well of a 24-well plate 
containing 1 mL LB with 50 mg/L ampicillin (to inhibit growth of E. coli) and 106 cells S. 
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aureus MRSA252. After 1 hour [Ru(2,9-Me2phen)2(dppz)]2+ was added, and the plates were 
incubated at 25 oC without agitation. Worm survival was scored daily.  
  
3. Results 
3.1 In vitro antibacterial activity 
Three Ru(II) complexes were tested for their antimicrobial activity: [Ru(phen)2(dpq)]2+, 
[Ru(bpy)2(dpqC)]2+, and [Ru(2,9-Me2phen)2(dppz)]2+. Initial tests on these compounds were 
performed using disc diffusion tests. All three Ru-complexes were active on the Gram-
positive B. subtilis, with [Ru(2,9-Me2phen)2(dppz)]2+ showing the largest zone of inhibition, 
followed by [Ru(bpy)2(dpqC)]2+ and [Ru(phen)2(dpq)]2+. In contrast, none of the compounds 
were active against the Gram-negative bacterium E. coli, suggesting that the compounds are 
only active on Gram-positive bacteria. 
B. subtilis is non-pathogenic, and it was therefore of interest to look at the sensitivity 
of Gram-positive pathogens towards the ruthenium intercalators. To test this we focused on 
clinical isolates of enterococci (Enterococcus faecalis BS385 and Enterococcus faecium 
E1162), and S. aureus. Of the enterococcal strains, E. faecium E1162 is resistant to several 
antibiotics, including ampicillin, kanamycin, and tetracycline, while the S. aureus isolates 
MRSA41 and MRSA252 are resistant to ampicillin, erythromycin, kanamycin, and 
ciprofloxacin for instance (Holden et al., 2004; data not shown). Disc diffusion tests again 
showed a similar trend as observed for B. subtilis, with [Ru(2,9-Me2 phen)2(dppz)]2+ the most 
active compound and [Ru(phen)2(dpq)]2+ the least active. Against enterococci only [Ru(2,9-
Me2 phen)2(dppz)]2+ was active.  
 To investigate this further we determined the MIC and MBC values. With B. subtilis 
and S. aureus strains this again showed the same order of activity of the compounds, with 
[Ru(2,9-Me2 phen)2(dppz)]2+ the most active and [Ru(phen)2(dpq)]2+ the least (Table 1). The 
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lowest MIC value was observed with [Ru(2,9-Me2 phen)2(dppz)]2+ on S. aureus MRSA252, 
with a value of 2 mg/L. MBC values were in all cases 2- or 4-fold the value of the MIC 
values, indicating that the compounds are mostly bactericidal.  
 Time-kill curves were performed in order to determine the rate of killing. For this 
purpose we only tested [Ru(2,9-Me2 phen)2(dppz)]2+ on S. aureus MRSA252, at a 
concentration of 0.5 × MIC (1 mg/L), 4 × MIC (= MBC, 8 mg/L) and 16 × MIC (= 4 × MBC, 
32 mg/L). As shown in Fig. 2 the rate of killing is clearly concentration-dependent. Without 
or with a final concentration of 1 mg/L [Ru(2,9-Me2 phen)2(dppz)]2+ cells continue to grow. 
At a concentration of 8 mg/L the bacteria die, with after 120 min an approximately 10-fold 
reduction in living bacteria. At a concentration of 32 mg/L the bacteria die more rapidly, with 
more than 99.9% of cells killed after 120 min (i.e. >3-log10 CFU/mL killing). 
 
3.2 Antibacterial activity in C. elegans 
C. elegans is a soil nematode that feeds on bacteria. It has been shown to be a useful infection 
model for several human pathogens (for a recent review, see O'Callaghan and Vergunst, 
2010). It has been shown that virulent strains of S. aureus kill C. elegans through colonization 
of the gut, but if exposure to the bacteria is limited to less than 8 hours then the lifespan of the 
nematodes is normal (Sifri et al., 2003). We therefore tested the ability of the most active 
complex in the in vitro screens, [Ru(2,9-Me2 phen)2(dppz)]2+, to rescue C. elegans from S. 
aureus infection. In the assay the nematodes were exposed for 1 hour to S. aureus cells after 
which different concentrations of [Ru(2,9-Me2 phen)2(dppz)]2+ were added. As shown in Fig. 
3, without compound all nematodes died within 6 days. Addition of 1 mg/L compound, which 
is below the MIC value, somewhat improved the rate of survival after 3 to 4 days, but at 
longer times of incubation the survival rate was not improved. By way of contrast, when 
either 8 or 32 mg/L [Ru(2,9-Me2 phen)2(dppz)]2+ was added nearly 80% of worms were still 
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alive after 6 days. That percentage was similar to the survival of worms not exposed to S. 
aureus and metal complex (data not shown), showing that [Ru(2,9-Me2 phen)2(dppz)]2+ is not 
toxic to C. elegans. Notably, we also tested toxicity of the compounds towards C. elegans in 
the presence of their normal food (E. coli OP50). Even at the highest concentration of 128 
µg/ml the nematodes appeared not to be affected for at least 72 hours, and survival rates with 
or without compounds were identical (data not shown). 
 
4. Discussion 
S. aureus MRSA252 belongs to a clinically significant clone that is important for a large 
proportion of MRSA outbreaks in many countries, including the UK and the USA (Holden et 
al., 2004). It is resistant against several antibiotics, yet we show here that this strain and two 
other S. aureus isolates are sensitive to the Ru(II) complexes assayed in this work, with the 
most effective compound being [Ru(2,9-Me2 phen)2(dppz)]2+. These complexes were not 
active against E. coli; it is conceivable that they are, for instance, not able to cross the outer 
membrane of E. coli, but further experiments need to be performed in order to test this. 
 The time to kill S. aureus with [Ru(2,9-Me2 phen)2(dppz)]2+ was relatively fast as 
compared to some antibiotics that are used for the treatment of S. aureus infections. For 
instance, vancomycin has been shown to require 24 hours to kill 99.9% of S. aureus cells at a 
concentration of 4 × MBC (Murillo et al., 2006). The time we observed for [Ru(2,9-Me2 
phen)2(dppz)]2+ to act is more comparable with e.g. quinolones such as levofloxacin or 
ciprofloxacin, which at similar concentrations require around 4 hours to reach 99.9% kill 
(Murillo et al., 2006; Gosbell, 2006).  
Considering only the intercalating ligands of the three ruthenium complexes tested, 
the antibacterial activity was in the order dppz>dpqC>dpq. This is also the order of their 
DNA-binding affinity, with dppz having the highest affinity and dpq the lowest (Delaney et 
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al., 2002). This is consistent with the antibacterial activity of the Ru complexes being 
governed by their DNA-binding characteristics. Note, however, that the peripheral ligands can 
also affect affinity. For instance, the published value of the binding constant for 
[Ru(phen)2(dpq)]2+ (O'Donoghue et al., 2005) is higher than that of [Ru(2,9-Me2 
phen)2(dppz)]2+ (Liu et al., 2001). A straightforward correlation between affinity and 
antimicrobial activity is therefore difficult to make. The reason for this may be that uptake in 
bacteria or binding to other targets such as proteins or ribosomes may also play a role. 
 In addition to the in vitro studies, we have shown that [Ru(Me2phen)2(dppz)]2+ is 
active in vivo as it prevented death of C. elegans nematodes infected with S. aureus. 
Importantly, the compound was also not toxic to C. elegans, which is a good indicator that 
they are also not toxic in higher eukaryotes (Leung et al., 2008). It needs to be pointed out, 
however, that we have not tested the compounds against mammalian cell cultures and it is 
clear that further tests are necessary to confirm that the Ru(II) complexes are not cytotoxic. It 
is nevertheless worth noting that, although C. elegans is a very simple model system, it does 
share several features with higher animals and has neurons, muscles, intestines, epidermis, 
and an innate immune response system (Artal-Sanz et al., 2006). C. elegans has been shown 
to be very valuable in antimicrobial drug discovery, as exemplified in studies on E. faecalis 
and Candida albicans (Moy et al., 2006; Okoli et al., 2009). Whether the Ru(II) complexes 
tested here will indeed be a starting point for the development of compounds appropriate for 
clinical use will require further investigation by analysing their toxicity, uptake, and mode of 
action. 
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Figure legends 
Figure 1. Structures of [Ru(phen)2dpq]2+, [Ru(bpy)2dpqC]2+, and [Ru(2,9-Me2phen)2dppz]2+
  
Figure 2. Time-kill assays of S. aureus MRSA252 in the presence or absence of 
[Ru(Me2Phen)2dppz]2+. Circles, 32 mg/L; diamonds, 8 mg/L; triangles, 1 mg/L; squares, no 
compound added. 
 
Figure 3. Survival of C. elegans in the presence or absence of [Ru(Me2Phen)2dppz]2+. Age-
synchronised nematodes were incubated in the presence of 106 cells of S. aureus MRSA252 
for one hour, after which compound was added. The number of alive and dead worms was 
scored daily. The error bars indicate the standard deviation from the average percentage of 
worms still alive. Circles, 32 mg/L; diamonds, 8 mg/L; triangles, 1 mg/L; squares, no 
compound added.
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Table 1. MIC and MBC valuesa   
B. subtilis MSSA160 MRSA41 MRSA252 Compound 
MIC MBC MIC MBC MIC MBC MIC MBC 
[Ru(phen)2dpq]2+  >128 >128 64 128 NDb ND ND ND 
[Ru(bpy)2dpqC]2+ 64 128 32 128 32 128 16 64 
[Ru(2,9-Me2 phen)2dppz]2+ 4 16 8 32 4 8 2 8 
       
aMIC and MBC values indicated in mg/L.  
bND, not determined as the strains indicated were resistant to the compound in the disc tests.
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